ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31

Erasca, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$13.62+0.23 (+1.72%)

Close on Oct 19, 2026

Market cap: $4.24B
P/E (TTM): –
Dividend yield: 0.00%

Erasca, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	93	115	104	112	74	30
General & Administrative	39	42	38	33	23	7.96
Operating Expenses	141	180	142	247	125	109
Operating Income	-141	-180	-142	-247	-125	-109
Other Non-Operating Income	16	18	16	4.65	2.12	7.59
Pretax Income	-125	-162	–	–	–	–
Income Tax Expense	0	0	–	–	–	–
Net Income incl. Noncontrolling Interests	-125	-162	-125	-243	-123	-102
Net Income	-125	-162	-125	-243	-123	-102
EPS (Basic)(per share)	-0.44	-0.69	-0.83	-1.99	-1.85	-4.83
EPS (Diluted)(per share)	-0.44	-0.69	-0.83	-1.99	-1.85	-4.83
Shares Outstanding (Basic, Weighted)(shares)	284	234	150	122	66	21
Shares Outstanding (Diluted, Weighted)(shares)	284	234	150	122	66	21
Dividend per Share(per share)	0.00	0.00	0.00	0.00	–	–
EBITDA	-138	-176	-138	-245	-124	-109

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -33.3%

Financial strength

Current ratio: 8.29
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 126.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 11.72
Dividend yield: 0.00%